Extended-Release RANCAD in the Patients With Stable Angina Pectoris

Primary objective is to to determine the effects of add-on RANCAD on exercise treadmill test (ETT) duration at trough plasma level of RANCAD level after 12-weeks therapy.

Inclusion criteria

• Male or female patients aged ≥ 20 years old
• A minimum 3-month history of stable angina
• Patients with diagnosis of coronary artery disease (CAD)
• Patients present with the symptoms of stable angina after withdrawn from other antianginal drugs and given the required background therapy for at least 7 days will be qualified for entering this study and performing 1st ETT qualifying test
• Patients developed exercise-induced ECG ischemiai during two qualifying exercise treadmill testsii. The difference between twoiii tests should be ≤ 20% of the longer test or ≤ 1 minute i. Exercise-induced ECG ischemia is defined as the new development of horizontal or down-sloping ST-segment depression of ≥1mm at 60-80ms after the J point; if patients with baseline ST depression at rest (<1mm), qualifying ST segment depression is defined as additional ST depression of at least 1 mm below the resting value ii. Exercise treadmill test (ETT) will be performed by Modified Bruce Protocol. iii. Two qualifying tests will be conducted 1 week apart, a 3rd ETT test will be performed ≤ 3 days when differences between previous two qualifying ETTs >20% of the longer test or >1 minute
• Willing and able to provide a written informed consent

Exclusion criteria

• Factors that might compromise ECG or ETT interpretation

• Patients with resting ST-segment depression ≥ 1mm in any lead
• Left bundle-branch block
• Patients implanted with pacemaker
• Patients under Digitalis therapy
• Patients with family history of (or congenital) long QT syndrome
• Patients with congenital heart disease
• Patients with uncorrected valvular heart disease
• Patients with unstable angina, or MI, or coronary revascularization procedure ≤ 2 months prior enter this study
• Female who is pregnant/lactating or planning to be pregnant, or female of childbearing potential* who is not using medically recognized method of contraception

*Other than those who have been surgically sterilized (defined as having undergone hysterectomy or bilateral oophorectomy or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year post-menopausal.

• Patients are under any one of the following conditions:

• New York Heart Association (NYHA) Class III or Class IV congestive heart failure (CHF)
• QTc > 450 msec at screening
• Active myocarditis, pericarditis, hypertrophic cardiomyopathy
• Uncontrolled hypertension (defined as SBP > 180 mmHg) Voltage criteria for left ventricular hypertrophy in the absence of repolarization abnormalities will not be exclusion criteria
• Use of any investigational product ≤ 4 weeks prior to screening
• Patients with severe hepatic disease (e.g., liver cirrhosis)
• Patients with impaired renal function (defined as serum Cr >1.5 mg/dl)
• Patients with any condition or disease which is considered not suitable for this study by investigator